Monitoring Liver Function During Tigecycline Use
Tigecycline, a glycylcycline antibiotic, carries a boxed warning for increased mortality risk and potential hepatotoxicity, including elevated liver enzymes (ALT/AST) and rare cases of liver failure. Regular liver function tests (LFTs) before, during, and after treatment detect early damage. Guidelines recommend baseline LFTs, monitoring every 3-7 days in high-risk patients, and weekly in others, with immediate discontinuation if transaminases exceed 5-10 times upper normal limit.[1][2]
Avoiding Use in Patients with Pre-Existing Liver Issues
Contraindicated or use with extreme caution in those with severe hepatic impairment (Child-Pugh C), active liver disease, or history of cholestasis. Dose adjustments apply for moderate impairment (Child-Pugh B): reduce loading dose to 50 mg and maintenance to 25 mg every 12 hours. No adjustment needed for mild cases, but close monitoring is essential.[1][3]
Drug Interaction Precautions
Tigecycline induces bile salt export pump (BSEP) inhibition, raising risk of cholestatic injury when combined with other BSEP inhibitors like rifampin or statins. Review concomitant meds; avoid or monitor closely with hepatotoxins (e.g., acetaminophen >2g/day, other antibiotics like azithromycin). Warfarin co-use prolongs INR, indirectly stressing liver metabolism—check coagulation frequently.[2][4]
Duration and Dosing Limits to Minimize Risk
Shortest effective course reduces cumulative exposure: typically 5-14 days for skin/skin structure or intra-abdominal infections. Avoid prolonged use beyond 14 days unless benefits outweigh risks, as hepatotoxicity correlates with duration. Standard adult dose is 100 mg loading, then 50 mg IV q12h; adhere strictly to avoid overdose.[1][3]
Patient Selection and Supportive Measures
Reserve for complicated infections where alternatives fail, per FDA black box. Screen for risk factors like age >65, obesity, alcohol use, or viral hepatitis. Hydration and nutritional support help, but no specific antidote exists—discontinue at first LFT elevation. Report severe cases to FDA MedWatch.[2][5]
Sources
[1] [Tygacil (tigecycline) FDA Label]
[2] [Tigecycline - StatPearls (NCBI)]
[3] [DrugPatentWatch - Tygacil]
[4] [Tigecycline Hepatotoxicity Review (PMC)]
[5] [FDA MedWatch]